Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.57 |
| ▸ | HTR2C | P28335 | 5/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | MLLT1 | Q03111 | 2/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12679631 | 0.91 | ABL1 (0.58) | MCHR1HTR2CCYP3A4CYP2C9MEN1 | |
| SCHEMBL12679630 | 0.91 | KMT2A (0.49) | MCHR1HTR2CHRH3CYP3A4CYP2C9 | |
| SCHEMBL9965098 | 0.91 | HIF1A (0.57) | MEN1KMT2AJAK3 | |
| SCHEMBL1016804 | 0.85 | CYP3A4 (0.55) | MCHR1HTR2CCYP3A4CYP2C9TRPV1 | |
| SCHEMBL9965064 | 0.84 | SMN1; SMN2 (0.52) | HTR2CMEN1KMT2AJAK3 | |
| SCHEMBL12679591 | 0.83 | KMT2A (0.71) | CYP3A4CYP2C9MEN1CYP1A2KMT2A | |
| SCHEMBL12679606 | 0.83 | KMT2A (0.65) | CYP3A4CYP2C9MEN1CYP1A2KMT2A | |
| SCHEMBL17195207 | 0.82 | KMT2A (0.47) | CYP3A4CYP2C9MEN1CYP1A2KMT2A | |
| SCHEMBL9965072 | 0.82 | ABL1 (0.49) | CYP3A4CYP2C9MEN1CYP1A2KMT2A | |
| SCHEMBL12681347 | 0.81 | KMT2A (0.59) | CYP3A4CYP2C9MEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273743-B2 | N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273743-B2 | N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-1745041-B1 | QUINOXALINE INHIBITORS OF THE HEDGEHOG SIGNALLING PATHWAY | GENENTECH INC (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | GENENTECH, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | GENENTECH, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | SHH, NR4A2, NR4A3 | MCHR1 1628/4885HTR2C 228/4885HRH3 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.